{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:43:20Z","timestamp":1788507800793,"version":"build-2803163510"},"reference-count":35,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["(N\/A) Research support for investigator initiated"],"award-info":[{"award-number":["(N\/A) Research support for investigator initiated"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,5,14]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery. There are no prospective data on the safety of stereotactic radiosurgery (SRS) concurrent with immune checkpoint inhibitor therapy for BM. This is the safety cohort of the phase I\/II investigator-initiated trial of SRS with nivolumab and ipilimumab for patients with BM from NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This single-institution study included patients with NSCLC with active BM amenable to SRS. Brain SRS and systemic therapy with nivolumab and ipilimumab were delivered concurrently (within 7\u2009days). The endpoints were safety and 4-month intracranial progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients were enrolled in the safety cohort, 10 of whom were evaluable for dose-limiting toxicities (DLTs). Median follow-up was 23 months (range 9.7\u201324.3 months). The median interval between systemic therapy and radiation therapy was 3\u2009days. Only one patient had a DLT; hence, predefined stopping criteria were not met. In addition to the patient with DLT, three patients had treatment-related grade \u22653 adverse events, including elevated liver function tests, fatigue, nausea, adrenal insufficiency, and myocarditis. One patient had a confirmed influenza infection 7 months after initiation of protocol treatment (outside the DLT assessment window), leading to pneumonia and subsequent death from hemophagocytic lymphohistiocytosis. The estimated 4-month intracranial PFS rate was 70.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Concurrent brain SRS with nivolumab\/ipilimumab was safe for patients with active NSCLC BM. Preliminary analyses of treatment efficacy were encouraging for intracranial treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-006871","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T16:20:18Z","timestamp":1688487618000},"page":"e006871","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I\/II trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02696993","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-156X","authenticated-orcid":false,"given":"Mehmet","family":"Altan","sequence":"first","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Welsh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-1327","authenticated-orcid":false,"given":"Chad","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Guha-Thakurta","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R","family":"Blumenschein","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Wefel","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol J","family":"Ghia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra N","family":"Yeboa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McAleer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina D","family":"Woodhouse","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"McGovern","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Y S","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina M","family":"Briere","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir Y","family":"Elamin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cascone","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6699","authenticated-orcid":false,"given":"Marcelo V","family":"Negrao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinandos","family":"Skoulidis","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V","family":"Heymach","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"2025100306200216000_11.7.e006871.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025100306200216000_11.7.e006871.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0320-3"},{"key":"2025100306200216000_11.7.e006871.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2025100306200216000_11.7.e006871.4","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1200\/JCO.2022.40.16_suppl.9010","article-title":"Updated analysis from the ATEZO-BRAIN trial: atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non\u2013small cell lung cancer with untreated brain metastases","volume":"40","author":"Nadal","year":"2022","journal-title":"JCO"},{"key":"2025100306200216000_11.7.e006871.5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"key":"2025100306200216000_11.7.e006871.6","first-page":"100205","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of keynote-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2025100306200216000_11.7.e006871.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.020"},{"key":"2025100306200216000_11.7.e006871.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30111-X"},{"key":"2025100306200216000_11.7.e006871.9","doi-asserted-by":"crossref","unstructured":"Borghaei H , Pluzanski A , Caro RB , et al . Abstract Ct221: Nivolumab (NIVO) + Ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases. Cancer Res 2020;80. doi:10.1158\/1538-7445.AM2020-CT221","DOI":"10.1158\/1538-7445.AM2020-CT221"},{"key":"2025100306200216000_11.7.e006871.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"2025100306200216000_11.7.e006871.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"2025100306200216000_11.7.e006871.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.009"},{"key":"2025100306200216000_11.7.e006871.13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"2025100306200216000_11.7.e006871.14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","article-title":"Local tumor response and survival outcomes after combined stereotactic radiosurgery and Immunotherapy in non-small cell lung cancer with brain metastases","volume":"132","author":"Singh","year":"2019","journal-title":"J Neurosurg"},{"key":"2025100306200216000_11.7.e006871.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.11.041"},{"key":"2025100306200216000_11.7.e006871.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000333","article-title":"Combined Immunotherapy with Nivolumab and Ipilimumab with and without local therapy in patients with Melanoma brain metastasis: a Decog* study in 380 patients","volume":"8","author":"Amaral","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100306200216000_11.7.e006871.17","doi-asserted-by":"crossref","unstructured":"Augustyn A , Patel R , Ludmir E , et al . Early concurrent Immunotherapy with stereotactic Radiosurgery is associated with prolonged survival and decreased distant brain failure in patients with newly diagnosed Melanoma brain metastases (Mbm). Neuro-Oncology 2020;22. doi:10.1093\/neuonc\/noaa215.766","DOI":"10.1093\/neuonc\/noaa215.766"},{"key":"2025100306200216000_11.7.e006871.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1525"},{"key":"2025100306200216000_11.7.e006871.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PLoS ONE"},{"key":"2025100306200216000_11.7.e006871.20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor Stroma and Microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front Immunol"},{"key":"2025100306200216000_11.7.e006871.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6"},{"key":"2025100306200216000_11.7.e006871.22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025100306200216000_11.7.e006871.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092572","article-title":"Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model","volume":"9","author":"Yoshimoto","year":"2014","journal-title":"PLoS One"},{"key":"2025100306200216000_11.7.e006871.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.004"},{"key":"2025100306200216000_11.7.e006871.25","doi-asserted-by":"crossref","first-page":"19740","DOI":"10.1038\/srep19740","article-title":"The role of PD-L1 in the radiation response and clinical outcome for bladder cancer","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"2025100306200216000_11.7.e006871.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2025100306200216000_11.7.e006871.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"2025100306200216000_11.7.e006871.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"2025100306200216000_11.7.e006871.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00507-6"},{"key":"2025100306200216000_11.7.e006871.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1"},{"key":"2025100306200216000_11.7.e006871.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"2025100306200216000_11.7.e006871.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30624-6"},{"key":"2025100306200216000_11.7.e006871.33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.21.2483"},{"key":"2025100306200216000_11.7.e006871.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70263-3"},{"key":"2025100306200216000_11.7.e006871.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9839"}],"updated-by":[{"DOI":"10.1136\/jitc-2023-006871corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:20:14Z","timestamp":1759497614000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,4]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/jitc-2023-006871"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006871","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}